Association of SLC1A1 gene polymorphism with obsessive compulsive disorder in a sample from southern India.

Shukla, Tulika; Nadella, Ravi Kumar; J, Reshma Jabeen Taj M; Ganesh, Suhas; Nestadt, Gerald; Purushottam, Meera; Jain, Sanjeev; Reddy, Y.C. Janardhan; Viswanath, Biju

doi:10.1037/pha0000348

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three patients were partial responders and were excluded from the analysis of treatment response. Responders were those who had >35% reduction in YBOCS (and CGI-I 1 or 2) following an SRI trial; non-responders were those with <25% reduction (and CGI-I >3) even after at least 2 SRI trials (Mataix-Cols et al, 2016; Shukla et al, 2020). All patients were on treatment with SRIs at the time of sample collection.…”

Section: Methodsmentioning

confidence: 99%

Cell cycle abnormality is a cellular phenotype in OCD

Manjappa

Naaz

Nadella

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Cell cycle abnormalities have been implicated in the pathology of neuropsychiatric disorders. Anti-obsessional agents like the serotonin reuptake inhibitor (SRI), fluoxetine, are known to cause cell cycle arrest. This study aimed at exploring cell cycle abnormalities in obsessive compulsive disorder (OCD) and the effect of in vitro Fluoxetine on lymphoblastoid cell lines (LCLs) derived from OCD patients and healthy controls. The patients had also been systematically characterized for SRI treatment response. LCLs were treated with 10&#956M of Fluoxetine for 24 hours and the percentage of cells in each phase of the cell cycle was determined by flow cytometry, after propidium iodide staining, and analysed using the software FlowJo. We observed a lower proportion of cells in the G2/M phase in OCD cases than controls. Among cases, clinical non-responders to SRI treatment had a lower proportion of cells in G2/M phase than the clinical responders. This suggests that there is a reduction of very specific cell cycle phase in OCD; and this difference is more pronounced in clinical non-responders. Although in-vitro fluoxetine treatment reduced the proportion of cells in G2/M phase overall , this was not specific to any group. The findings suggest that cell cycle G2/M phase dysregulation could be peripheral cellular phenotype for OCD, and a marker for SRI non-response in the clinic.

show abstract

Section: Methodsmentioning

confidence: 99%

Cell cycle abnormality is a cellular phenotype in OCD

Manjappa

Naaz

Nadella

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hanna et al (Hanna et al, 2002) showed a strong link between human SLC1A1 gene (Solute Carrier Family 1 Member 1), encoding for the glutamate transporter EAAT3 (Excitatory Amino Acid Transporter 3) in families with OCD. Allelic distribution of several SLC1A1 polymorphisms was associated with OCD diagnosis in family-based association (Arnold et al, 2006;Dickel et al, 2006;Samuels et al, 2011;Shugart et al, 2009;Stewart et al, 2007) and case-control studies (de Salles Andrade et al, 2019;Shukla et al, 2020;Wang et al, 2010;Wendland et al, 2009). In a pharmacogenetic study (Abdolhosseinzadeh et al, 2019b), a significant association between the G allele of both rs2228622 and rs3780413 and fluvoxamine treatment response was observed.…”

Section: Glutamatergic Systemmentioning

confidence: 99%